Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 1 examiners • 0 of 2 (0%) have an AI response strategy ready
Zero Gravity Solutions Inc. is managing 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. Both of these actions are located within a single distinct art unit, reflecting a narrow technical focus for the company's current applications. The company is dealing with a sole distinct examiner for both of these matters, which centralizes the prosecution process and allows for a more consistent approach to claim amendments and arguments.
SCHLIENTZ, NATHAN W is the busiest examiner, responsible for 2 pending office actions. Since the busiest examiner pending count matches the total number of pending actions, this individual has complete oversight of the company's current pending portfolio. This allows the company to develop a singular, cohesive strategy for its Biotechnology & Pharmaceuticals filings, focused on the specific feedback and requirements of this one examiner. Practitioners should focus on building a productive dialogue with this examiner to advance the company's intellectual property goals.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SCHLIENTZ, NATHAN W | 2 | 41.3% | -18.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18834973 | PLANT PRIMING COMPOSITIONS AND METHODS OF USE THEREOF | SCHLIENTZ, NATHAN W | — |
| Art Unit | Apps |
|---|---|
| 1616 | 2 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19067410 | PLANT PRIMING COMPOSITIONS AND METHODS OF USE THEREOF | SCHLIENTZ, NATHAN W | 1616 | §102DP | Final Rejection | 3d overdue | Pending | Feb 28, 2025 |
| 18834973 | PLANT PRIMING COMPOSITIONS AND METHODS OF USE THEREOF | SCHLIENTZ, NATHAN W | 1616 | §103§112 | Non-Final OA | — | Pending | Jul 31, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialZero Gravity Solutions Inc. has 2 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Nathan W Schlientz has the most, with 2 of Zero Gravity Solutions Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
